Evidence Repository - Clinical Genome Resources

The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Link to SEPIO compliant JSON-LD document

Criteria Specification: CSpec Registry PDF

Variant: NM_000277.2(PAH):c.535T>A (p.Tyr179Asn)

CA229613

102729 (ClinVar)

Gene: PAH

Condition: phenylketonuria

Inheritance Mode: Autosomal recessive inheritance

Link to MONDO

UUID: 1530f57a-9096-4f98-a934-15ce8f576c73

HGVS expressions

NM_000277.2:c.535T>A

NM_000277.2(PAH):c.535T>A (p.Tyr179Asn)

NC_000012.12:g.102855307A>T

CM000674.2:g.102855307A>T

NC_000012.11:g.103249085A>T

CM000674.1:g.103249085A>T

NC_000012.10:g.101773215A>T

NG_008690.1:g.67296T>A

NG_008690.2:g.108104T>A

NM_000277.1:c.535T>A

NM_001354304.1:c.535T>A

NM_000277.3:c.535T>A

ENST00000307000.7:c.520T>A

ENST00000549111.5:n.631T>A

ENST00000551988.5:n.556T>A

ENST00000553106.5:c.535T>A

Likely Pathogenic

PP3 PM3 PM2 PP4_Moderate

Expert Panel

Phenylketonuria VCEP

Evidence Links 1

Evidence submitted by expert panel

Phenylketonuria VCEP

PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP3: Deleterious effect predicted in SIFT, Polyphen-2, MutationTaster. REVEL=0.929; PP4_Moderate: Detected in 1 PKU patient, primary BH4 deficiency excluded. Upgraded per ClinGen PAH EP. (PMID:23430918); PM3: Detected with c.1066-11G>A (P) (PMID:23430918). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3).

PP3

Deleterious effect predicted in SIFT, Polyphen-2, MutationTaster. REVEL=0.929

PM3

Detected with c.1066-11G>A (P)

Patient genotype: p.Y179N: c.1066-11G>A PubMed:23430918

PM2

Absent from ExAC, gnomAD, 1000G, ESP

PP4_Moderate

Detected in 1 PKU patient, primary BH4 deficiency excluded. Upgraded per ClinGen PAH EP.

Detected in 1 PKU patient: previously documented Phe level >360 umol/L and a Phe level >450 umol/L at the screening visit. Patients with a diagnosis of primary BH4 deficiency were excluded from the study. PubMed:23430918

Approved on: 2018-08-10

Published on: 2019-08-17

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.